Cresco Labs

Cresco Labs earns a Neutral rating, with the composite score near 53 and conviction at one out of five. Fundamentals provide the principal support, scoring in the high 60s on strong gross-margin, operating-margin, and cash-generation subscores. Regulatory contributes a high-50s result, reflecting a favorable jurisdiction posture and no enforcement hits, but weak filing cadence limits the pillar. Market evidence scores 40 because institutional pricing feeds provide no available quote, while editorial registers 30 following no newsroom or brief activity. The resulting mix supports the Neutral band: operating execution offsets limited growth, sparse disclosures, unavailable pricing confirmation, and low coverage momentum.

Licensed fundamentals data show year-over-year revenue contraction of approximately 9%, leaving the revenue-growth subscore in the low 40s. That decline contrasts with a gross margin just above 50% and an operating margin near 7.4%, producing margin subscores above 80 and establishing profitability as the strongest feature set. EBITDA totaled roughly $123 million, yet net income remained a loss of about $134 million. The EBITDA-positive profile supports operating cash-generation capacity, but it does not erase the stretched financial condition or the bottom-line deficit. Primary regulatory filings show no recorded filing date, no events across either the 90-day or 180-day windows, and no enforcement hits. CIN newsroom coverage also records no recent news or brief hits, reinforcing the low editorial contribution.

The clearest rerating catalyst sits within the fundamentals pillar. Cresco’s margin structure demonstrates that the operating platform can generate positive EBITDA despite contracting sales, while the 50%-plus gross margin and positive operating margin create meaningful earnings leverage if revenue stabilizes. A sustained improvement in sales would strengthen the weakest fundamentals subscore, validate the existing margin profile, and raise confidence beyond the current one-out-of-five level. Better filing cadence could improve regulatory visibility, but it remains secondary to fundamental execution given the pillar hierarchy. The single most important signal to watch is a return to positive year-over-year revenue growth without sacrificing the gross margin above 50%.